share_log

Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024

Benzinga ·  Feb 26 16:27
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment